Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
Verastem nixes KRAS G12C plans in non-small cell lung cancer
Newer G12C inhibitors are “establishing a new benchmark with higher response rates,” Verastem’s chief medical officer said in explaining the move.
Angus Liu
Jan 2, 2026 10:10am
FDA approves J&J's new challenge to Tagrisso
Dec 18, 2025 10:40am
Merck partner Kelun touts ph. 3 win for ADC in first-line NSCLC
Nov 24, 2025 10:56am
FDA signs off on Bayer's HER2-mutated lung cancer med Hyrnuo
Nov 19, 2025 4:52pm
Akeso details ivonescimab's 1st overall survival win
Nov 7, 2025 11:30am
Merck grows more ambitious about 'workhorse' TROP2 ADC
Oct 20, 2025 4:00pm
